See more : Sentage Holdings Inc. (SNTG) Income Statement Analysis – Financial Results
Complete financial analysis of Acer Therapeutics Inc. (ACER) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acer Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Stella Diagnostics Inc. (SLDX) Income Statement Analysis – Financial Results
- Shibaura Machine Co.,Ltd. (6104.T) Income Statement Analysis – Financial Results
- Asian Paints Limited (ASIANPAINT.NS) Income Statement Analysis – Financial Results
- Zee Entertainment Enterprises Limited (ZEEL.BO) Income Statement Analysis – Financial Results
- Footway Group AB (publ) (FOOT-PREF.ST) Income Statement Analysis – Financial Results
Acer Therapeutics Inc. (ACER)
About Acer Therapeutics Inc.
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | 249.57K | 816.24K | 2.90M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 266.04K | 687.51K | 2.54M |
| Gross Profit | 0.00 | 1.26M | 0.00 | 0.00 | 432.12K | -246.30K | 2.91M | 2.56M | 1.27M | 1.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.45K | 46.45K | 0.00 | 0.00 | 3.92K | 16.05K | -16.47K | 128.73K | 363.10K |
| Gross Profit Ratio | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 100.00% | 100.00% | -6.60% | 15.77% | 12.51% |
| Research & Development | 11.92M | 6.51M | 11.85M | 13.85M | 12.45M | 8.73M | 6.50M | 10.04M | 12.12M | 9.18M | 6.32M | 3.34M | 2.58M | 2.11M | 8.39M | 13.07M | 7.61M | 9.89M | 632.62K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 0.00 | 2.22M | 2.02M | 0.00 | 0.00 | 5.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.69M | 10.70M | 10.95M | 16.05M | 9.26M | 5.22M | 3.12M | 4.26M | 3.83M | 3.67M | 2.51M | 2.41M | 2.22M | 2.02M | 3.34M | 3.42M | 5.46M | 550.18K | 3.13M | 120.35K | 130.29K | 528.35K | 975.65K | 685.81K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.63K | 68.70K | 2.15K | 37.91K | 303.68K | 219.94K | 169.30K | 216.62K | 237.16K | 246.15K | 1.82M | 1.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 528.35K | 975.65K | 730.47K |
| Cost & Expenses | 24.61M | 17.21M | 22.80M | 29.90M | 21.71M | 13.95M | 9.86M | 14.65M | 16.34M | 13.19M | 9.13M | 5.97M | 4.97M | 4.35M | 11.97M | 16.74M | 14.90M | 12.20M | 3.76M | 121.84K | 160.30K | 794.38K | 1.66M | 3.27M |
| Interest Income | 1.82K | 49.27 | 13.58K | 471.27K | 412.55K | 14.85K | 0.00 | 0.00 | 15.46K | 14.99K | 280.00 | 932.00 | 1.66K | 1.76K | 100.24K | 477.61K | 688.30K | 81.93K | 5.99K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 101.43K | 0.00 | 0.00 | 0.00 | 987.00 | 245.06K | 0.00 | 0.00 | 1.98K | 2.27M | 350.30K | 3.14K | 500.65K | 278.13K | 19.98K | 16.10K | 984.00 | 7.32M | 868.93K | 55.06K | 54.16K | 55.40K | 33.71K | 13.95K |
| Depreciation & Amortization | -198.47K | -54.76K | 96.20K | -8.21K | 27.74K | 4.00K | 238.13K | 351.40K | 387.78K | 335.60K | 303.68K | 210.25K | 168.84K | 214.85K | 234.33K | 232.96K | 1.82M | 7.25M | 1.02M | 1.48K | 12.95K | 15.40K | 19.41K | 19.13K |
| EBITDA | -24.55M | -15.88M | -22.73M | -28.34M | -21.25M | -13.95M | -6.70M | -2.57M | -14.66M | -11.53M | -8.83M | -5.76M | -4.80M | -7.32M | -11.77M | -18.10M | -13.23M | -4.95M | -2.74M | -201.83K | -113.49K | -531.89K | -827.39K | -551.31K |
| EBITDA Ratio | 0.00% | -1,270.09% | 0.00% | 0.00% | -4,929.34% | 5,656.94% | -195.37% | -459.26% | -1,152.81% | -910.49% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -38,961.47% | -28,472.35% | 0.00% | 0.00% | -5,155.33% | -707.07% | -213.13% | -101.37% | -19.00% |
| Operating Income | -24.61M | -15.95M | -22.80M | -29.90M | -21.71M | -13.95M | -7.99M | -12.09M | -15.07M | -11.92M | -9.13M | -5.97M | -4.97M | -4.35M | -11.97M | -16.74M | -14.90M | -12.20M | -3.76M | -117.92K | -144.25K | -544.82K | -846.92K | -367.37K |
| Operating Income Ratio | 0.00% | -1,265.75% | 0.00% | 0.00% | -5,024.81% | 5,662.97% | -275.08% | -473.10% | -1,184.68% | -941.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -36,030.81% | -32,067.06% | 0.00% | 0.00% | -3,012.06% | -898.67% | -218.31% | -103.76% | -12.66% |
| Total Other Income/Expenses | -1.62M | 574.40K | -82.62K | -1.02M | 433.10K | -246.30K | -1.28M | 74.61K | 15.62K | -4.73M | 202.96K | -3.14K | -498.99K | 2.91M | 115.15K | 2.68M | 838.74K | -7.21M | -860.56K | 85.39K | -17.80K | 2.47K | -120.00 | 203.07K |
| Income Before Tax | -26.24M | -15.37M | -22.89M | -29.42M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -32.53K | -162.05K | -542.34K | -847.04K | -164.30K |
| Income Before Tax Ratio | 0.00% | -1,220.16% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -830.91% | -1,009.56% | -217.32% | -103.77% | -5.66% |
| Income Tax Expense | 1.62M | -645.31K | 11.81K | -537.75K | -432.12K | 246.30K | 1.04M | -4.74K | 4.13K | 2.31M | -202.96K | 5.97M | 5.47M | 1.43M | 11.85M | 14.67M | 14.06M | 19.41M | 4.62M | -30.33K | 54.91K | 52.93K | 33.83K | -189.12K |
| Net Income | -27.86M | -14.73M | -22.90M | -28.88M | -21.28M | -14.19M | -7.98M | -12.02M | -15.05M | -16.66M | -8.93M | -5.97M | -5.47M | -1.43M | -11.85M | -14.67M | -14.06M | -19.41M | -4.62M | -87.59K | -199.16K | -597.74K | -880.75K | -178.25K |
| Net Income Ratio | 0.00% | -1,168.94% | 0.00% | 0.00% | -4,924.81% | 5,762.97% | -274.69% | -470.18% | -1,183.45% | -1,315.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -31,576.68% | -30,261.37% | 0.00% | 0.00% | -2,237.24% | -1,240.76% | -239.51% | -107.90% | -6.14% |
| EPS | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
| EPS Diluted | -1.77 | -1.03 | -2.06 | -2.86 | -2.49 | -3.84 | -11.72 | -21.26 | -39.65 | -91.56 | -113.13 | -77.65 | -93.91 | -33.48 | -329.28 | -642.07 | -764.35 | -363.69 | -2.15K | -385.85 | -4.86K | -13.90K | -18.35K | -3.79K |
| Weighted Avg Shares Out | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
| Weighted Avg Shares Out (Dil) | 15.77M | 14.27M | 11.12M | 10.09M | 8.56M | 3.69M | 680.67K | 565.35K | 379.63K | 181.92K | 78.94K | 76.87K | 58.24K | 42.83K | 35.99K | 22.84K | 18.39K | 53.38K | 2.15K | 227.00 | 41.00 | 43.00 | 48.00 | 47.00 |
Russian LNG on the rise in EU – report
Russian LNG accounts for one-fifth of all EU imports, the economic bloc’s energy watchdog (ACER) has reported Read Full Article at RT.com...
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Acer Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
NEWTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced that...
PC demand is back, says Acer CEO who sees robust growth in the 'foreseeable future'
Acer CEO Jason Chen said that PC demand hit a bottom in May, but demand has come back since then.
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)....
ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc. - ACER
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acer Therapeutics Inc. (NasdaqCM: ACER) to Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)....
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.
Shareholder Alert: Ademi LLP investigates whether Acer Therapeutics Inc. has obtained a Fair Price in its transaction with Zevra
MILWAUKEE , Aug. 31, 2023 /PRNewswire/ -- Ademi LLP is investigating Acer (Nasdaq: ACER) for possible breaches of fiduciary duty and other violations of law in its transaction with Zevra. Click here to learn how to join the action https://www.ademilaw.com/case/acer-therapeutics-inc or call...
ACER Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Acer Therapeutics Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Acer Therapeutics Inc. (NASDAQ: ACER) to Zevra Therapeutics, Inc. for 0.121 of a share of Zevra's common stock for each share of Acer's common...
Why Is Acer Therapeutics (ACER) Stock Up 85% Today?
Acer Therapeutics (NASDAQ: ACER ) stock is taking off on Thursday after the pharmaceutical company announced an acquisition deal with Zevra Therapeutics (NASDAQ: ZVRA ). According to a press release from the company, Zevra Therapeutics will be acquiring it with $15...
Acer Therapeutics Reacquires Worldwide Development, Commercialization and Economic Rights to OLPRUVA™ from Relief Therapeutics, Excluding the Geographical Europe
NEWTON, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it...
Source: https://incomestatements.info
Category: Stock Reports